55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

Key Takeaways Explain This Topic AI

Primary hyperparathyroidism (PHPT; 85% solitary parathyroid adenoma) and malignancy account for >90% of all hypercalcemia cases; PHPT is characterized by hypercalcemia (or high-normal ionized calcium) paired with an inappropriately elevated or normal intact PTH level, hypophosphatemia, and hypercalciuria, whereas malignancy-associated hypercalcemia features completely suppressed intact PTH.

Familial Hypocalciuric Hypercalcemia (FHH) is an autosomal dominant inactivating mutation in the calcium-sensing receptor (CaSR) gene that causes lifelong benign hypercalcemia with normal/elevated PTH; it is definitively distinguished from PHPT by the 24-hour urine calcium-to-creatinine clearance ratio (CCCR): a CCCR <0.01 indicates FHH, where parathyroidectomy is ineffective and strictly contraindicated, whereas a CCCR >0.02 confirms PHPT.

Parathyroidectomy in asymptomatic PHPT is indicated if any of the following criteria are met: serum calcium >1.0 mg/dL above the upper limit of normal (>11.5 mg/dL), age <50 years, bone mineral density T-score <= -2.5 at the lumbar spine, hip, or 33% distal radius (or fragility fracture), eGFR <60 mL/min, or 24-hour urine calcium >400 mg/day with nephrolithiasis/nephrocalcinosis.

Acute severe hypercalcemia (>14.0 mg/dL or symptomatic) mandates immediate aggressive resuscitation with IV 0.9% normal saline (200-300 mL/hr) to restore volume and drive calciuresis, combined with subcutaneous calcitonin (rapid onset, transient efficacy due to tachyphylaxis) and intravenous bisphosphonates (zoledronic acid 4 mg IV, onset 48-72 hours, prolonged duration); loop diuretics (furosemide) are strictly contraindicated until intravascular volume is completely restored.

Prolactinomas are the most common functional pituitary adenoma; initial therapy is medical with dopamine agonists (cabergoline preferred over bromocriptine due to superior efficacy and tolerability) which normalizes prolactin and shrinks tumors in >85-90% of cases, reserving transsphenoidal surgery for medical failures; acromegaly is screened via serum IGF-1, confirmed by failure of GH suppression on oral glucose tolerance testing, and treated primarily with transsphenoidal surgical resection.

Last updated: September 2026

Differential Diagnosis & Pathophysiology of Hypercalcemia

Calcium homeostasis is tightly orchestrated by the coordinated actions of parathyroid hormone (PTH) , 1,25-dihydroxyvitamin D ( 1 , 25 [ O H ] 2 D 1,25[OH]_2D 1 , 25 [ O H ] 2 D , calcitriol) , and the calcium-sensing receptor (CaSR) across bone, kidneys, and the gastrointestinal tract. In clinical practice, more than 90% of all hypercalcemia cases are attributable to either Primary Hyperparathyroidism (PHPT) (the predominant etiology in ambulatory outpatients) or Malignancy (the predominant etiology in hospitalized, acutely ill patients).

Calcium Homeostasis & Laboratory Assessment

Normal Serum Calcium Reference Range : Total serum calcium is normally 8.5 to 10.5 mg/dL (2.12 to 2.62 mmol/L); ionized calcium is 4.65 to 5.25 mg/dL (1.16 to 1.31 mmol/L).

Albumin Correction Formula :

Approximately 40% to 45% of circulating calcium is bound to plasma proteins, predominantly albumin. In states of hypoalbuminemia, total serum calcium appears spuriously low while the physiologically active ionized calcium fraction remains normal.

Total calcium must always be adjusted using the standard correction equation: Corrected Calcium (mg/dL) = Measured Total Calcium (mg/dL) + 0.8 × [ 4.0 − Serum Albumin (g/dL) ] \text{Corrected Calcium (mg/dL)} = \text{Measured Total Calcium (mg/dL)} + 0.8 \times [4.0 - \text{Serum Albumin (g/dL)}] Corrected Calcium (mg/dL) = Measured Total Calcium (mg/dL) + 0.8 × [ 4.0 − Serum Albumin (g/dL) ]

Whenever diagnostic uncertainty persists, direct measurement of free ionized calcium using a heparinized whole-blood or serum sample is the definitive reference standard.

Physiological Actions of Parathyroid Hormone (PTH)

Secreted by parathyroid chief cells in response to hypocalcemia sensed by the cell-surface CaSR:

Bone : Binds to osteoblast receptors, upregulating RANK-ligand (RANKL) expression. RANKL binds RANK on osteoclast precursors, inducing osteoclast differentiation and activating osteoclastic bone resorption, releasing calcium and phosphate into circulation.

Kidney (Distal Convoluted Tubule) : Stimulates active transcellular reabsorption of filtered calcium, decreasing renal calcium clearance.

Kidney (Proximal Convoluted Tubule) :

Phosphaturic Action : Inhibits sodium-phosphate cotransporters (NaPi-IIa and NaPi-IIc), dramatically increasing urinary phosphate excretion and inducing hypophosphatemia.

1-Alpha-Hydroxylase Activation : Upregulates the CYP27B1 enzyme, converting 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol) .

Gastrointestinal Tract : Calcitriol acts on enterocytes to markedly stimulate active intestinal calcium and phosphate absorption.

Etiologic Differential Diagnosis of Hypercalcemia DIFFERENTIAL DIAGNOSIS OF HYPERCALCEMIA

Etiology Key Mechanism & Clinical Setting PTH Level
═════════════════════════════════════════════════════════════════════════════════════════════
Primary Hyperparathyroidism Autonomous parathyroid adenoma (85%) Elevated or
(PHPT) or hyperplasia (15%); asymptomatic outpatient Inappropriately Normal

Malignancy: Humoral (HHM) Tumor secretion of PTHrP (80% of cancer Ca) Fully Suppressed
(Squamous cell lung, head/neck, renal, uro) (< 10-15 pg/mL)

Malignancy: Osteolytic Local cytokine osteolysis (multiple myeloma, Fully Suppressed
Metastases breast cancer, extensive bone metastases) (< 10-15 pg/mL)

Malignancy / Granulomatous: Autonomous extra-renal 1-alpha-hydroxylase Fully Suppressed
Calcitriol-Mediated (Hodgkin/non-Hodgkin lymphoma, sarcoidosis) (High 1,25[OH]2D)

Familial Hypocalciuric Inactivating CaSR gene mutation; lifelong Normal or
Hypercalcemia (FHH) mild hypercalcemia; LOW urinary calcium Mildly Elevated

Medications: Thiazides Reduces renal calcium clearance Normal or Suppressed
Medications: Lithium Shifts CaSR set-point upward Normal or Mildly Elevated
Milk-Alkali Syndrome Calcium carbonate + alkali ingestion Fully Suppressed
Thyrotoxicosis Thyroid hormone-induced osteoclastosis Fully Suppressed
═════════════════════════════════════════════════════════════════════════════════════════════

Primary Hyperparathyroidism vs. Familial Hypocalciuric Hypercalcemia (FHH)
Clinical Presentation of Primary Hyperparathyroidism (PHPT)

Primary hyperparathyroidism results from autonomous, unregulated parathyroid hormone secretion:

Pathology : Solitary benign parathyroid adenoma (85% of cases), multiglandular four-vessel hyperplasia (15%; sporadic or familial as part of MEN1 or MEN2A), and parathyroid carcinoma (<1%; marked by severe calcium >14-15 mg/dL, palpable neck mass, and marked local tissue invasion).

Symptomatic Spectrum : In modern clinical practice, >80% of patients with PHPT in North America are asymptomatic , discovered incidentally on routine automated biochemical panels. When symptomatic, manifestations follow the classic mnemonic "bones, stones, abdominal groans, and psychic moans" :

Bones : Preferential demineralization of cortical bone over trabecular bone. The highest degree of bone mineral density loss occurs at the 33% (one-third) distal radius (which is 95% cortical bone), whereas the lumbar spine (predominantly trabecular bone) is relatively spared early in disease. In severe advanced untreated disease, osteitis fibrosa cystica develops (subperiosteal bone resorption of the phalanges, "salt-and-pepper" skull, bone cysts, and osteoclast-rich "brown tumors").

Stones : Recurrent nephrolithiasis (calcium oxalate and calcium phosphate stones) in 15% to 20% of patients; nephrocalcinosis.

Abdominal Groans : Constipation, anorexia, nausea, peptic ulcer disease (hypercalcemia stimulates gastric G-cells to hypersecrete gastrin and acid), and acute pancreatitis (calcium activates intrapancreatic trypsinogen).

Psychic Moans : Lethargy, depression, fatigue, cognitive slowing, memory impairment, sleep disturbances.

Cardiovascular : Hypertension, left ventricular hypertrophy, shortened QT interval on ECG.

Laboratory Profile in PHPT

Serum Total and Ionized Calcium : Elevated (or fluctuating into the high-normal range in normocalcemic PHPT).

Serum Intact PTH : Inappropriately elevated or "inappropriately normal" . In the presence of hypercalcemia, normal physiological parathyroid feedback dictates that intact PTH should be suppressed to <10 to 15 pg/mL. An intact PTH level in the upper-normal or even mid-normal range (e.g., 45 pg/mL with a calcium of 11.2 mg/dL) represents autonomous, pathological hypersecretion and confirms the diagnosis!

Serum Phosphate : Low or low-normal (<2.5 mg/dL) due to PTH-induced renal phosphaturia.

Serum Chloride-to-Phosphate Ratio : A ratio > 33 strongly favors PHPT, reflecting distal renal tubular acidosis caused by PTH-induced bicarbonate wasting.

Alkaline Phosphatase : Elevated in patients with high-turnover skeletal bone disease.

24-Hour Urinary Calcium : Typically elevated (>250-300 mg/day) due to the overwhelming filtered calcium load exceeding distal reabsorptive capacity.

Familial Hypocalciuric Hypercalcemia (FHH): The Great Mimicker

Genetic Pathophysiology : Autosomal dominant loss-of-function inactivating mutation in the CASR gene on chromosome 3q (encoding the calcium-sensing receptor) or downstream G-protein signaling components ( GNA11 , AP2S1 ).

The Blunted Calcium Set-Point : Parathyroid chief cells and renal tubular epithelial cells fail to properly sense circulating extracellular calcium. The set-point for calcium sensing is shifted to the right: the parathyroid requires a much higher calcium level to inhibit PTH secretion, and the renal thick ascending limb senses circulating calcium as abnormally low, driving avid, lifelong renal calcium reabsorption .

Clinical Manifestations : Completely benign, lifelong, asymptomatic mild hypercalcemia. Patients DO NOT develop nephrolithiasis, fractures, bone loss, or renal insufficiency , and they have a normal life expectancy.

CRITICAL CLINICAL PEARL: THE SURGICAL CONTRAINDICATION :

Parathyroidectomy is completely ineffective in FHH because the inactivating receptor mutation is present throughout all tissues. Surgical resection fails to normalize serum calcium and subjects the patient to lifelong iatrogenic hypoparathyroidism!

Patients with FHH must be identified to prevent unnecessary neck exploration .

The Diagnostic Discriminator: The CCCR Formula

Distinguishing PHPT from FHH requires calculating the 24-Hour Urine Calcium-to-Creatinine Clearance Ratio (CCCR) from a fasting 24-hour urine collection and concurrent serum chemistry: CALCIUM-TO-CREATININE CLEARANCE RATIO (CCCR)

CCCR = [ 24-Hour Urine Calcium (mg/dL) x Serum Creatinine (mg/dL) ] /
[ Serum Calcium (mg/dL) x 24-Hour Urine Creatinine (mg/dL) ]

Diagnostic Cutoffs:

─────────────────────────────────────────────────────────────────────────────
CCCR < 0.01 Highly suggestive of FAMILIAL HYPOCALCIURIC HYPERCALCEMIA (FHH)
(Sensitivity ~85%, Specificity ~88%)

DO NOT OPERATE! Parathyroidectomy is contraindicated.
Confirm with CASR gene genetic testing and family screening.

CCCR > 0.02 Confirms PRIMARY HYPERPARATHYROIDISM (PHPT)

High urinary calcium clearance; evaluate for surgical resection.

CCCR 0.01 to 0.02 Indeterminate "Gray Zone"
Coexisting severe Vitamin D deficiency in PHPT can falsely lower
urinary calcium into this range. Correct Vitamin D (replete 25-OH-D

to >30 ng/mL) and repeat 24-hour urine collection.

─────────────────────────────────────────────────────────────────────────────

Surgical Indications in Asymptomatic PHPT & Preoperative Localization

While parathyroidectomy is universally indicated for all patients with symptomatic PHPT (nephrolithiasis, fragility fractures, symptomatic hypercalcemia), the vast majority of patients are asymptomatic.

International Consensus Guidelines for Parathyroidectomy in Asymptomatic PHPT

The American Association of Endocrine Surgeons (AAES) and international consensus guidelines establish definitive criteria for surgical referral in asymptomatic patients. Meeting ANY ONE of the following criteria warrants parathyroidectomy: GUIDELINE CRITERIA FOR PARATHYROIDECTOMY IN ASYMPTOMATIC PHPT

Clinical Domain Specific Threshold Criteria Indicating Surgery
═════════════════════════════════════════════════════════════════════════════════════════════
Serum Calcium Serum total calcium > 1.0 mg/dL (> 0.25 mmol/L) above the upper limit
of normal (e.g., > 11.5 mg/dL if laboratory ULN is 10.5 mg/dL)

Age Age < 50 years (patients face decades of progressive bone/renal loss)

Skeletal Health • Bone mineral density (DEXA) T-score <= -2.5 at lumbar spine, total
hip, femoral neck, or 33% (one-third) distal radius; OR
History of a fragility fracture; OR
Asymptomatic vertebral fracture on spine imaging (VFA or X-ray)

Renal Health • eGFR < 60 mL/min/1.73m² (without alternative explanation); OR
24-hour urinary calcium excretion > 400 mg/day (> 10 mmol/day)
WITH an increased stone-risk biochemical profile; OR
Nephrolithiasis or nephrocalcinosis detected on abdominal imaging
(ultrasound, non-contrast CT, or plain radiograph)
═════════════════════════════════════════════════════════════════════════════════════════════

Preoperative Localization Imaging vs. Diagnosis :

Preoperative localization studies (e.g., Technetium-99m Sestamibi SPECT/CT scan , high-resolution neck ultrasound, or 4D-CT) are performed solely to assist the endocrine surgeon in planning a targeted, minimally invasive parathyroidectomy versus bilateral neck exploration.

CRITICAL BOARD EXAM PEARL : Localization scans are NEVER used to diagnose hyperparathyroidism ! A negative sestamibi or ultrasound scan does not exclude PHPT, nor does it disqualify a patient from surgical parathyroidectomy.

Medical Management for Non-Surgical Candidates :

If surgery is refused or contraindicated: Ensure adequate oral hydration (2-3 liters/day); avoid thiazide diuretics and lithium; maintain moderate dietary calcium intake (do not restrict calcium, which drives compensatory PTH elevation); consider Cinacalcet (a calcimimetic that binds CaSR, suppressing PTH and normalizing serum calcium) or oral bisphosphonates (alendronate) to preserve skeletal bone density.

Malignancy-Associated Hypercalcemia & Acute Severe Hypercalcemic Crisis

Hypercalcemia of malignancy is the most common cause of hypercalcemia in hospitalized patients, carrying a grave prognosis (median survival 1 to 3 months). It develops via three distinct pathophysiological mechanisms: MECHANISMS OF HYPERCALCEMIA OF MALIGNANCY

Mechanism Tumor Types & Biology Endocrine Laboratory Profile
═════════════════════════════════════════════════════════════════════════════════════════════════════
Humoral Hypercalcemia Squamous cell carcinomas (lung, head/neck, • Intact PTH fully suppressed (<10 pg/mL)
of Malignancy (HHM) esophagus, cervix); renal cell, bladder Ca; • Serum PTHrP markedly elevated
(~80% of cancer cases) Tumor secretes Parathyroid Hormone-Related • Calcitriol (1,25[OH]2D) low/normal
Protein (PTHrP), binding PTH-1 receptors • Serum phosphate low (phosphaturia)

Osteolytic Bone Multiple myeloma, breast cancer, • Intact PTH fully suppressed (<10 pg/mL)
Metastases non-small cell lung cancer; • Serum PTHrP normal or low
(~20% of cancer cases) Tumor cells in marrow secrete local • Calcitriol normal or low
cytokines (RANKL, IL-1, IL-6, TNF-alpha) • Extensive bone lesions on imaging

Calcitriol-Mediated Hodgkin and Non-Hodgkin Lymphoma; • Intact PTH fully suppressed (<10 pg/mL)
Hypercalcemia systemic granulomatous diseases • Calcitriol (1,25[OH]2D) markedly elevated
(<1% of cancer cases) (Sarcoidosis, Tuberculosis, Berylliosis); • 25-OH-Vitamin D normal
Autonomous 1-alpha-hydroxylase in macrophages • Serum phosphate normal/high
═════════════════════════════════════════════════════════════════════════════════════════════════════
Acute Severe Hypercalcemic Crisis: The Multimodal Emergency Protocol

Severe hypercalcemia is defined as a total serum calcium > 14.0 mg/dL (or ionized calcium >3.0 mmol/L), or moderate elevation (12.0-13.9 mg/dL) accompanied by acute altered mental status, severe dehydration, or cardiac dysrhythmias. High calcium activates CaSR in the medullary collecting duct, blunting ADH responsiveness and causing nephrogenic diabetes insipidus , profound polyuria, volume depletion, prerenal azotemia, and decreased calcium filtration, establishing a vicious cycle of accelerating hypercalcemia. ACUTE SEVERE HYPERCALCEMIA EMERGENCY RESUSCITATION

Therapeutic Modality Mechanism, Dosing & Onset Critical Clinical Pearls
═════════════════════════════════════════════════════════════════════════════════════════════════════
Step 1: Aggressive IV Isotonic Expands extracellular volume, Infuse 200 to 300 mL/hr (titrated to
0.9% Normal Saline (NaCl) restores renal blood flow, promotes cardiac/renal status). Lowers calcium

urinary sodium and calcium excretion by 1.5 to 2.0 mg/dL over first 24-48 hrs.

Step 2: Subcutaneous or Inhibits osteoclastic bone resorption Dose: 4 to 8 IU/kg SC or IM every 12 hrs.

Intramuscular Calcitonin and increases renal calcium excretion Rapid onset (2-4 hrs), but TACHYPHYLAXIS

(receptor down-regulation) occurs at 48 hrs.

Step 3: Intravenous Potent pyrophosphate analogs; bind Zoledronic Acid 4 mg IV over 15 min

Bisphosphonates hydroxyapatite, induce osteoclast (or Pamidronate 60-90 mg IV over 2-4 hrs).

(Zoledronic Acid) apoptosis, stopping bone resorption Delayed onset (takes 48-72 hrs to work),

but prolonged duration (lasts 2-4 weeks).

Alternative: Denosumab Monoclonal antibody inhibiting RANKL; Dose: 120 mg SC weekly during induction.

(Subcutaneous) blocks osteoclast maturation Agent of choice for BISPHOSPHONATE-

REFRACTORY hypercalcemia or eGFR <30.

Targeted: Glucocorticoids Inhibits macrophage 1-alpha-hydroxylase Prednisone 20-40 mg PO daily or IV
(Prednisone / Hydrocortisone) activity; reduces gut Ca absorption hydrocortisone; indicated specifically for

LYMPHOMA, SARCOIDOSIS, VITAMIN D TOX.

LAST-LINE / RESTRICTED: Inhibits loop of Henle calcium NEVER GIVE FUROSEMIDE UNTIL VOLUME

Loop Diuretics (Furosemide) reabsorption STATUS IS COMPLETELY RESTORED!

Reserved strictly for volume overload.

═════════════════════════════════════════════════════════════════════════════════════════════════════

Pituitary Disorders: Prolactinomas, Acromegaly & Compressive Mass Effects

Pituitary adenomas are benign monoclonal neoplasms arising from adenohypophyseal corticotroph, lactotroph, somatotroph, thyrotroph, or gonadotroph cells, classified by size and functional hormone secretion.

Sellar Anatomy & Macroadenoma Compressive Mass Effects

The pituitary gland rests within the bony sella turcica, immediately inferior to the optic chiasm and flanked bilaterally by the cavernous sinuses (transmitting cranial nerves III, IV, V 1 V_1 V 1 , V 2 V_2 V 2 , and VI, and the internal carotid arteries):

Microadenomas (< 10 mm in diameter) : Confined to the sella turcica; do not compress adjacent neurovascular structures. Present exclusively with endocrine hypersecretion syndromes.

Macroadenomas (>= 10 mm in diameter) : Expand beyond the sella, producing characteristic compressive mass effects:

Bitemporal Hemianopsia : Suprasellar extension compresses the decussating nasal retinal nerve fibers in the central optic chiasm, producing selective loss of the peripheral temporal visual fields in both eyes.

Headache : Upward stretching of the pain-sensitive diaphragma sellae.

Cranial Nerve Palsies : Lateral invasion into the cavernous sinus impairs ocular motility (diplopia, ptosis; CN III palsy most common).

Hypopituitarism : Compression of normal surrounding non-adenomatous anterior pituitary tissue leads to sequential, progressive loss of pituitary hormones (classic order of loss: GH ──► LH/FSH ──► TSH ──► ACTH ).

Pituitary Apoplexy : Acute, catastrophic ischemic infarction or hemorrhage into a preexisting macroadenoma, presenting with sudden-onset thunderclap headache, acute visual acuity collapse, ophthalmoplegia, and life-threatening adrenal crisis . Requires emergent high-dose IV hydrocortisone and urgent transsphenoidal neurosurgical decompression.

Prolactinoma (Lactotroph Adenoma): Most Common Functional Adenoma

Prolactinomas represent 40% to 50% of all pituitary adenomas . Prolactin secretion is uniquely subject to tonic, constitutive inhibition by hypothalamic dopamine acting on lactotroph D2 receptors. PROLACTINOMA: CLINICAL PRESENTATION & DIAGNOSTIC WORKUP

Demographic Group Clinical Features Diagnostic Evaluation & Prolactin Levels
═════════════════════════════════════════════════════════════════════════════════════════════════════
Premenopausal Women • Oligomenorrhea or amenorrhea • Fasting morning serum prolactin

Bilateral galactorrhea (breast milk) • Serum Prolactin > 200-250 ng/mL:

• Infertility (hyperprolactinemia Virtually pathognomonic for prolactinoma

suppresses hypothalamic GnRH pulses) • Mild Prolactin Elevation (20-100 ng/mL):

• Early diagnosis (microadenomas) Rule out secondary etiologies:

Drugs (antipsychotics, metoclopramide)
Men & Postmenopausal • Decreased libido, erectile dysfxn - Primary Hypothyroidism (high TRH stimulates PRL)
Women • Gynecomastia, oligospermia - Stalk Effect (macroadenoma blocks dopamine)
Late presentation with macroadenomas - Chronic kidney disease, cirrhosis
Visual loss (bitemporal hemianopsia) • Dedicated Pituitary MRI with Gadolinium
═════════════════════════════════════════════════════════════════════════════════════════════════════

Management: The Medical-First Paradigm :

Unlike virtually all other solid intracranial neoplasms, the first-line treatment for prolactinomas is MEDICAL THERAPY WITH DOPAMINE AGONISTS, NOT SURGERY !

Cabergoline (First-Line Choice) :

Potent, long-acting D2 receptor agonist dosed once or twice weekly (0.25 to 1.0 mg twice weekly).

Normalizes serum prolactin in >85% to 90% of patients , restores gonadal function, and induces dramatic tumor shrinkage in >80% of microadenomas and macroadenomas , rapidly decompressing the optic chiasm and reversing visual field defects.

Substantially superior gastrointestinal tolerability (less nausea, vomiting, dizziness) and higher efficacy compared to bromocriptine.

Bromocriptine (Alternative) : Short-acting daily oral dopamine agonist; historically preferred in women desiring immediate pregnancy due to extensive safety records, though cabergoline is widely used.

Indications for Transsphenoidal Surgery : Reserved strictly for prolactinomas refractory to high-dose dopamine agonists, patients intolerant of dopamine agonist psychiatric or cardiac valvular side effects, or tumors causing progressive visual loss despite medical therapy.

Acromegaly (Somatotroph Adenoma): Growth Hormone Excess

Acromegaly is caused by autonomous hypersecretion of Growth Hormone (GH) by a somatotroph adenoma (typically a macroadenoma at diagnosis due to an insidious 8- to 12-year diagnostic delay). (In pediatric patients before epiphyseal growth plate fusion, GH hypersecretion produces Gigantism ).

Pathophysiology & IGF-1 Biology :

Pituitary GH stimulates the liver to synthesize and release Insulin-Like Growth Factor 1 (IGF-1) , which mediates peripheral somatic tissue hypertrophy, bone remodeling, and metabolic disruption.

Why Random GH is Useless : Circulating GH is secreted in pulsatile, episodic bursts with a plasma half-life of only 20 minutes, frequently dropping to undetectable levels in normal individuals and spiking under physical stress or fasting. A single random serum GH level is completely non-diagnostic.

In contrast, serum IGF-1 has a stable 15-hour half-life bound to IGF-binding protein 3 (IGFBP-3), providing an integrated biochemical measure of 24-hour GH exposure.

Clinical Manifestations :

Acral & Soft Tissue Overgrowth : Progressive enlargement of the hands and feet (patients report increasing shoe, ring, and glove sizes); broadening of fingers ("spade-like" hands).

Craniofacial Changes : Coarsening of facial features, prominent frontal bossing, enlargement of the nose, thickening of lips, severe macroglossia (scalloped tongue), and prognathism (mandibular overgrowth resulting in underbite, malocclusion, and widening teeth spacing).

Cardiovascular Complications (Leading Cause of Mortality) : Biventricular concentric hypertrophy, acromegalic cardiomyopathy, diastolic heart failure, accelerated coronary atherosclerosis, and secondary hypertension.

Metabolic & Respiratory : Severe obstructive sleep apnea (OSA) (present in >70% of patients due to pharyngeal soft tissue hypertrophy and macroglossia); insulin resistance, impaired fasting glucose, and secondary Type 2 Diabetes Mellitus (GH directly opposes insulin action, stimulating hepatic gluconeogenesis).

Oncologic Surveillance : Markedly increased incidence of adenomatous colonic polyps and colorectal cancer , warranting baseline screening colonoscopy at diagnosis and regular surveillance.

Musculoskeletal : Severe degenerative arthropathies, kyphoscoliosis, and carpal tunnel syndrome (bilateral median nerve compression from synovial thickening). DIAGNOSTIC & THERAPEUTIC PROTOCOL FOR ACROMEGALY

Step Procedure & Clinical Threshold Interpretation
═════════════════════════════════════════════════════════════════════════════════════════════
Step 1: Initial Screening Measure Serum Insulin-Like Growth Factor 1 (IGF-1)
Serum IGF-1 elevated above age- and sex-matched reference range

confirms high suspicion of GH hypersecretion.

Step 2: Confirmatory Test Oral Glucose Tolerance Test (75g OGTT) with GH Measurement
Physiological Response: Oral glucose load suppresses GH < 1.0 ng/mL

(or < 0.4 ng/mL on ultrasensitive assays).

• Acromegaly Confirmed: FAILURE OF GH SUPPRESSION (<1.0 ng/mL)

demonstrates autonomous, unregulated somatotroph secretion.

Step 3: Imaging Dedicated Pituitary MRI with Gadolinium
Visualizes pituitary adenoma (macroadenoma in >75-80% of cases)

and delineates cavernous sinus extension.

First-Line Therapy: Transsphenoidal Surgical Resection (TSS)

Surgical Extirpation • Unlike prolactinomas, SURGERY IS FIRST-LINE for acromegaly!

• Cures 70-85% of microadenomas and 40-50% of macroadenomas.

Medical Therapy Indicated for residual or unresectable disease following surgery:

(Second-Line) • Somatostatin Receptor Ligands (Octreotide LAR, Lanreotide): First-line

medical therapy; inhibits GH release via SSTR2/SSTR5 receptors.

• GH Receptor Antagonist (Pegvisomant): Blocks peripheral IGF-1 synthesis.

• Dopamine Agonists (Cabergoline): Effective in tumors co-secreting prolactin.